Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Mark Vandewalker, MD

Allergy Specialist and Partner
Allergy & Asthma Consultants Of The Ozarks Ltd
Member of the Healthcare Council

Mark Vandewalker, MD, is an Allergy Specialist at Allergy and Asthma Consultants and he is the Medical Director at Clinical Research of the Ozarks in Missouri. Dr. Vandewalker is board-certified in Pediatric Allergy and has been practicing for almost 25 years. His areas of expertise include allergic rhinitis, difficult asthma, chronic sinusitis, food and drug allergy, and recurrent hives. He has co-authored over 24 articles, delivered 300+ lectures, and served in leadership roles of several professional organizations. Dr. Vandewalker has been an investigator in almost 400 clinical trials of new allergy and asthma drugs and consulted for numerous pharmaceutical companies and respiratory care endeavors. (This is me - Update Profile)


Employment History
1990 - present Allergy Specialist and Partner
Allergy & Asthma Consultants Of The Ozarks Ltd
1990 - present Medical Director
Clinical Research of the Ozarks, Inc.

GLG Study Groups with Mark Vandewalker, MD(?)

View All Study Groups with Mark Vandewalker, MD

GLG NewsSM Analyses by Mark Vandewalker, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Will Xolair Become Obsolete in the Treatment of Allergies? | 06-10-2008
Analysis of: Investigational Anti-IgE Antibody Promising as Extracorporeal Allergy Therapy | www.medscape.com
Author: Mark Vandewalker, MD, Allergy Specialist and Partner, Allergy & Asthma Consultants Of The Ozarks Ltd

This recent report characterizes a newly discovered anti-IgE monoclonal antibody (mAb12) which appears dramatically more potent than omalizumab (Xolair) in its ability to reduce systemic IgE levels. If further studies confirm this enhanced reduction of IgE and IgE-bearing cells, mAb12 has significant...

Impact of Symbicort on the U.S. Asthma Market | 06-11-2007
Analysis of: AstraZeneca Launches New Advance In Asthma Treatment - Symbicort Maintenance And Reliever Therapy (Symbicort SMART) | www.medicalnewstoday.com
Author: Mark Vandewalker, MD, Allergy Specialist and Partner, Allergy & Asthma Consultants Of The Ozarks Ltd

Symbicort is AstraZeneca's answer to Advair, presently the number one combination ICS/LABA in the U.S. for treating moderate to severe asthma. Symbicort will not, however, have an indication for quick relief of bronchospasm as it does in many European countries. Nevertheless, Symbicort appears to be...

GLG InstituteSM Seminars with Mark Vandewalker, MD(?)

 
Mark Vandewalker, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Mark Vandewalker, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-04T09:45:15.927